Many Faces One voice 

Lung Cancer Europe

Lung Cancer Europe is the voice of lung cancer patients, their families and survivors at a European level and it aims to raise awareness for lung cancer.

News

Other news

UP
    DOWN

    About Luce

    Lung Cancer Europe is the voice of lung cancer patients, their families and survivors at a European level. LuCE provides a European platform for already existing lung cancer patient advocacy groups and supports the establishment of national lung cancer patient groups in different European countries where such groups do not yet exist.

    LuCE aims to raise awareness about inequities regarding the access to lung cancer treatment and care in Europe. Moreover, it advocates European policies that will lead to improvements in lung cancer prevention, early detection, treatment and care. LuCE also supports national lung cancer patient groups in helping raise awareness for lung cancer among the European public.

    Our objectives

    • Reduce the mortality of lung cancer.
    • Promote the best possible treatment of the different types of lung cancer.
    • Equal access to lung cancer care throughout Europe.
    • Raise public awareness for lung cancer about symptoms, early detection and treatment
    • Reduce the stigma associated with lung cancer and more compassion for lung cancer patients and their loved ones
    • Increase European funding allocated to lung cancer research.

    Click here for our Articles of Association.

    • Board Members

    • Stefania Vallone

      President

      Italy

      mailto:stefania.vallone@womenagainstlungcancer.eu

    • Ewelina Szmytke

      Vice-President

      Poland

      mailto:ewelinaszmytke@wp.pl

    • Regine Deniel Ihlen

      Treasurer

      Norway

      mailto:regine.deniel.ihlen@lungcancereurope.eu

    • Tommy Björk

      Board Member

      Sweden

      mailto:tommy.bjork@lungcancereurope.eu

    • Christian Schmitt-Plank

      Board Member

      Germany

      mailto:kcsphd@gmail.com

    Position paper

    Lung Cancer Europe advocates European policies that will lead to improvements in lung cancer prevention, early detection, treatment and care.

    Download

    11/10/2015 – LuCE EU Position Paper 2015: “With an estimated incidence of over 449 000 cases per year, lung cancer is one of the most common malignancies in Europe."

    Members

    Lung Cancer Europe provides a European platform for national lung cancer patient advocacy groups and supports the establishment of those groups in countries where such groups do not yet exist.

    Full members

    • Organisation
    • AEACaP
    • Bundesverband Selbsthilfe Lungenkrebs e.V.
    • Forum Lungenkrebs Schweiz
    • Longkanker Nederland
    • Lungecancerförbundet Stödet
    • Lungekreftforeningen
    • National Lung Cancer Forum for Nurses (NLCFN)
    • Patientforeningen Lungekræft
    • Pulmonale
    • Women Against Lung Cancer in Europe (WALCE)
    • Stowarzyszenie Walki z Rakiem Płuca
    • Landesverband Baden-Württemberg für Lungenkrebskranke und deren Angehörige e.V
    • Country
    • Spain
    • Germany
    • Switzerland
    • Netherlands
    • Sweden
    • Norway
    • United Kingdom
    • Denmark
    • Portugal
    • Italy
    • Poland
    • Germany

    Associate members

    • European Thoracic Oncology Platform (ETOP)
    • European School of Oncology (ESO)
    • Fundación MÁS QUE IDEAS
    • Društvo onkoloških bolnikov Slovenije
    • Switzerland
    • Italy
    • Spain
    • Slovenia

    Click here for more information on how LuCE works with sponsors.

    Scientific advisory board

    Prof. Silvia Novello

    (University of Torino, Italy)

    Is a professor in the thoracic oncology unit at San Luigi Hospital in Orbassano, Italy, part of the University of Turin. Prof. Novello advocates a multidisciplinary approach towards diagnosis of lung cancer and stresses the need for modernizing lung cancer research. Her research interests include thoracic malignancies, gender differences in lung cancer, experimental studies on sarcoidosis, on basic and clinical applied research on lung cancer, including pharmacogenomics. She is involved in several European clinical trials evaluating new approaches in diagnosis and lung cancer therapy.

    Prof. Jesper Holst Pedersen

    (University of Copenhagen, Denmark)

    Is an associate professor and consultant in thoracic surgery at Copenhagen University Hospital, Rigshospitalet. He is chairman of the surgical subcomittee of the IASLC strategic screening advisory committee. Prof. Peterson advocates for the early detection of patients with lung cancer through CT scans and calls for the EU and its member states to prepare guidelines on screening to ensure adequate follow up and management.

    Prof. dr. Harry Groen

    (University of Groningen, The Netherlands)

    With his international NELSON study, prf. Groen has shown the importance of annual screening to help early detection of lung cancer among (former) smokers. He supports LuCE's calls on the Europe Union to increase the research funding allocated to lung cancer research and to develop guidelines on lung cancer screening and diagnosis.

    Prof. dr. António M. F. Araùjo

    (Centro Hospitalar do Porto and University of Porto, Portugal)

    António M. F. Araújo is the Head of the Service of Medical Oncology at Centro Hospitalar do Porto, and is Assistant Professor at Institute of Biomedical Sciences Abel Salazar – Porto University, since Mars 2014. Member of the Portuguese National Council for Oncology, since 2013, and member of the Advisory Board of the Portuguese Health Regulatory Authority, since February 2015.

    Supporters

    Contact

    LuCE

    c/o ETOP

    3008 Bern

    Switzerland

    luce@etop-eu.org